<SEC-DOCUMENT>0001493152-23-036631.txt : 20231010
<SEC-HEADER>0001493152-23-036631.hdr.sgml : 20231010
<ACCEPTANCE-DATETIME>20231010070014
ACCESSION NUMBER:		0001493152-23-036631
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231010
FILED AS OF DATE:		20231010
DATE AS OF CHANGE:		20231010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		231315587

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>October
2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>London</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2023, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing, that it has filed an Investigational New
Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain
(NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA., a copy of which is furnished as Exhibit
99.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    October 9, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News Announcement, dated October 9, 2023</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 50.25pt; width: 132pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (&ldquo;NCP&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
                                            plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram
                                            Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients
                                            with NCP.</I></B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Second
                                            clinical indication for OK-101 which is currently in 240-patient Phase 2 clinical trial to
                                            treat dry eye disease, with top-line data anticipated in December 2023.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, October 9, 2023. OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative
therapies for the treatment of inflammatory dry eye disease (&ldquo;DED&rdquo;), a multi-billion-dollar market, and for neuropathic corneal
pain, a severe ocular condition with no FDA approved therapy, today announced that it filed an Investigational New Drug (IND) application
with the U.S. Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment
is planned to commence during Q1 2024 following IND allowance by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NCP
remains a major unmet medical need for the ocular community, as there is no FDA-approved drug to treat NCP and this trial provides the
opportunity to establish OK-101&rsquo;s potential to treat this condition. The open-label trial will provide an opportunity to evaluate
the safety and efficacy of OK-101 for NCP in a real-world clinical setting, fostering a better understanding of its potential benefits
for patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCP trial will be led by Pedram Hamrah, MD, Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service
and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist,
Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is a member of OKYO&rsquo;s Scientific Advisory Board
and plans to serve as Principal Investigator of the study, which will be conducted at Tufts Medical Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;NCP,
which can exhibit as a severe, chronic or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently
treated by various topical and systemic treatments in an off-label fashion,&rdquo; said Dr. Hamrah. &ldquo;However, there are no approved
commercial treatments currently available for this condition, and consequently we are looking forward to initiating the clinical trial
to investigate the potential efficacy of OK-101 to treat symptoms of NCP.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited about OK-101&rsquo;s dual combination of anti-inflammatory ocular activity and NCP reducing activity and are eager to evaluate
this drug to treat NCP while awaiting the top-line data for OK-101 from the ongoing Phase 2 DED trial which is planned for released in
December 2023,&rdquo; said Dr. Gary S. Jacob, CEO of OKYO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce
a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing
activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the
inclusion of the lipid &lsquo;anchor&rsquo; contained in the drug molecule to enhance the residence time of OK-101 within the ocular
environment. OK-101 is currently in a Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the OK-101 Phase 2 DED Trial Design</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
phase 2, multi-center, randomized, double&ndash;blinded, placebo-controlled study is designed to enroll approximately 240 subjects with
DED who are being randomly divided into 3 cohorts of 80 patients. Participants are being selected based on specific inclusion and exclusion
criteria. The three cohorts include one cohort treated with placebo, a second cohort treated with 0.05% OK-101, and the third cohort
receiving 0.1% OK-101. The drug and placebo, respectively, are being administered in both eyes twice daily for 12 weeks. The duration
of a patient&rsquo;s treatment is approximately 14 weeks, including a 2-week run-in period, to address the placebo effect, which is common
for trials involving a pain component, followed by 12 weeks of treatment. The protocol for the study includes two prespecified primary
endpoints and a number of secondary endpoints. Further details regarding the specifics of the trial are posted on the clinicaltrials.gov
public website (clinicaltrials.gov Identifier: NCT05759208 or <U>https://clinicaltrials.gov/ct2/results?term=Okyo&amp;cond=Dry+Eye+Syndromes).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory
DED) and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development
of novel molecules to treat inflammatory DED and ocular pain. OKYO presently has a 240-patient phase 2 trial of OK-101 underway to treat
patients with DED, and also has plans underway for the opening of a 40-patient trial of OK-101 to treat NCP in patients with this debilitating
condition. For further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements made in this announcement are forward-looking statements, including with respect to the anticipated timing of completion of
enrolment of the Company&rsquo;s Phase 2 trial of topical ocular OK-101 to treat DED and the release of top-line data therefrom. These
forward-looking statements are not historical facts but rather are based on the Company&rsquo;s current expectations, estimates, and
projections about its industry, its beliefs, and assumptions. Words such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo;
&lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &lsquo;seeks,&rsquo; &lsquo;estimates,&rsquo; and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties,
and other factors, some of which are beyond the Company&rsquo;s control, are difficult to predict, and could cause actual results to
differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective
security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required
by law or by any appropriate regulatory authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit the Company&rsquo;s website at <U>www.okyopharma.com </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The person who arranged for the release
of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enquiries:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
    Relations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
    (0)20 7495 2379</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "; 9L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWCD=:3>A[!_PT!;_ /0NR_\ @6/_ (BC_AH"W_Z%V7_P+'_Q%>:_\*Z\8?\
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MSJ-'^.$&K:W8::-!DB-W<1P"0W(.W>P7.-O.,UZS7R'X-_Y'CP__ -A*W_\
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M ")NA_\ 8/M__1:U\@5]!^!?BKX;3POIVG:K=_8;RTA2V*O&Q1P@P&# $#(
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MU+#>6MP<07,,I_V'#?RI6&?)/C+_ )'CQ!_V$KC_ -&-7>? 3_D:M2_Z\O\
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MQ7X:M?%6ARZ?<'9(/G@E'6.0#@^X[$>A]<&MNBJC)Q=UN*45)69\U:7K>O\
M@#7+B!,Q2QMLN+28$QOZ$C/T(8=N^#S[1X6^(>C>)PD ?['?G_EUF;[QX^XW
M1NOL>#Q4/Q \$)XKT\3VP1-4MU_=.>/,7KL)_EZ'ZFOGVYMI[.YDMKF)XIHV
M*O&XP5/H17KJ-+%QOM(\MRJ8:5MXGUK17SQH'Q.\0Z'LBEG&H6H(S%=$LP&>
M=K]0<<#.0/2O1-*^,/A^\55U".YT^7:2Q9?-C!ST!7YC_P!\BN*I@ZL-E?T.
MN&*ISW=C=UKP58ZI,]U;R-9W3G<[(N5<]R5]?<$=<G-<Z? VO)PMQ9,,X'[Q
MAQZ_=KK[;Q=X<NXXWAUS3SY@RJM<*K?BI((/L15\ZE8*F]KVV"8SN,JX_G6:
MJ58:?FC7EA+5,XBU^'U]++_Q,;^)(@1Q;Y9F'?D@8_(UVNF:79Z19K;6<01!
MR3U9CZD]S6;>^-?#-A"99]<L2 <%891*V?\ =3)_2N%\0_&6%8Y(- M'>0Y4
M75R,*.>JIU/'KCW!JU"O6TMI]R(=2E3U;.P\:^,K7PEIA;*2ZC*I^SVY/4_W
MF_V1^O3W'EGPQTF?Q#XV?5KP^:EHQN9G< [Y6)V_CG+9_P!FN)O[^[U2^FO;
MZ=Y[F9MSR.>2?Z#L . .*V;+QIJ^E:&-)TJ1;& EFEDB'[V5F R2QZ= !MQ@
M =>M>C'#.G2<8;O=GGRQ"G44I;+H?0NL>(=(T"'S=4OX;8$95&.789Q\JCD]
M>PKS>^^).N>*+LZ7X-TV5'89,\@4R <<XSM0=1DDYR,8-8'A?X:ZOXGE&I:O
M++:V<Q$AEE.Z:?)Y(!Z9'\3>H(!%>U:/HFG:!8+9:9;)!"#DXY+'U8GDGZ_3
MI7#)4:&GQ2_ [(NK6_NQ_$XSP[\++.UF_M#Q%.=5U!VWLKL6B!X.3GESP?O<
M'/3O7H$44<$210QK'&BA41!@*!T  Z"GT5RU*LZCO)G3"G&"M%!6+XQ_Y$C7
M_P#L&W'_ *+:MJL7QC_R)&O_ /8-N/\ T6U3'=%/9GS3X'\'2>-M8GTZ*]6T
M,5N9][1[\X95QC(_O?I7>_\ "@+O_H88?_ 4_P#Q5<?\-/%UAX,\0W.H:C#<
MRQ2VK0J+=59MQ=6YW,.,*:]2_P"%\>%_^?#6/^_,7_QRNVHZJE[NQR05.WO'
M$>(_@MJ>A:'<ZG!J=O>+:H998_+,;; ,DCD@X'...GX5U/P+\07U_9ZEI-Y<
M/-%:"-[;>2Q13D%<G^$87 [<U4\5_&K2-4\-7^G:9IU]Y]W"T!:Y5$5%8$$_
M*S$G!Z<4WX V,P.M:@R,(&\J%'(X9AN+ ?0%?^^A42YG3?.5'E51<AV'QC_Y
M)K?_ /72'_T8M9/P&_Y$J^_["+_^BXZUOC'_ ,DUO_\ KI#_ .C%KQ?PC?\
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MO_7G)_*O /A]\/O^$[.H_P#$S^P_8_+_ .7?S=^_=_M+C&W]:]_\?_\ )/\
M7?\ KSD_E7@/P^^(!\"_VB1I?VX7GE#_ %_E[-F__9.<[OTK2CS<CY=R:MN=
M<VQVW_#/O_4S_P#DA_\ ;*Y_Q?\ !VZ\+Z!<:O#J\5Y%;[3(C0&)L$A<CE@>
M3[<?E6__ ,-!'_H61_X'_P#VNL3Q7\7KSQ;H4NAVNB+;?:V5783F9F 8$*H"
MKR2!Z\9X[U<?;7UV^1$O96T.R^!_B*^U71+_ $R]E>9=.:/R)';+!'#83Z#8
M<?7'0"M_XN?\DPU?_MC_ .CDK&^"WA;4= T?4+W4[>6UEOI$"02IM=40-AB.
MHR7/! Z9[UL_%W_DF&K_ /;'_P!')6,K>VT[FJO[/4\*^'WC2;P7KXN&#R6%
MQB.[A4\E>S#_ &ER2/7)'&<CZGM[B&[MHKFWD62"9!)&ZG(92,@CV(KYX\)^
M T\7_"Z]GLXD&LVNH2&!R=IE7RXR8R??J,]#W )K3^#_ (X?2;__ (1/5MZ0
MRRE;5I,@PRD\QD'H&/Y-V^;(TK14[N.Z,Z4G&R>S/>*\J^+_ (_.C6;>'M*G
M7^T+E/\ 2G4Y,$1'3V9A^('/<&NL\>>,K?P9X?>[/ER7TV4M('/WW]2!SM7.
M3^ R"17DGPS\&7/C/7Y?$VN@3V,<Q=_.&?M4W7&.FT$@GL>%P1G&5**2YY;(
MTJ2?P1W(?@42/'=S@]=/DS_WW'7T57SK\"_^1[N/^P?)_P"AQU]%4\1\84?@
M$9E12S$*H&22< "OFKQ=K-[\4/B!;Z?I1#6P<V]D&)5=O5Y6[C.,GC.U0,9%
M=]\:?&G]FZ8/#=C)BZO4W73*2#'#_=X[M@@_[(.1\PKG/A)JGA+PQ9W&IZMJ
M\,6J7.8ECVN3%$#T.%QEB,]3P%Z<BJI1<8\]M>A-22E+D,[X8>*I_!GBR;0M
M68PV=Q,8)TD?Y;><':&[CJ-I/ Q@DX6OHROG+XM7?AC6]0@UO0=3BGNY,17<
M2JP+8'RN,J.PVGG^[@=37IGPG\:_\)/X>%C>S;M5L $D+OEIH_X9.>I['KR,
MG[PHK1YESV]0IRL^0]!HHHKE.@**** "BBB@ KDO&O@2Q\66ID3;;ZG&/W5P
M!][_ &7]1[]1V[@];15PG*$N:+U)G!37+(^6=<\/:GX<OC::E;-$V3LDQE)
M,<JW0CD?3/.#677UAJ&G6>JV;VE_;17%N_5)%R/J/0^XY%><ZW\&=/N6>71K
MZ2S8@D03#S$SV ;[RCW.ZO7I8^#5JFC/+JX*2UAJ>*T5W-[\)?%=JRB&"VO
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M+N71;O4)=11-T$=Q+&4<CG:<(.2,@<CDC/%87P7\9G3-4;PU?R;;6\?-L7(
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M#Z$=".Q!%6Z;'%'#&(XD5$'15& /PIU8&H4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
